Type 1 Diabetes

Autoimmune Type 1 Diabetes (T1D) can be detected through islet autoantibody testing years before symptoms appear.^1-2 The video here explains how the condition progresses silently through presymptomatic stages, with beta cell destruction occurring long before symptom onset and clinical diagnosis.^4-8

Parent's experiences of stage 3 diagnosis of T1D.

Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).¹

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.^1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.^3,4

Autoimmune type 1 diabetes (T1D) is a progressive disease in which the decline in beta cell function usually begins months or sometimes years before clinical symptoms are observed.^1–3 You can identify such patients at risk of developing autoimmune T1D before clinical symptoms are noticed by you or your patient.³

Individuals living with other associated autoimmune diseases like celiac disease or autoimmune thyroid disease, are at an increased risk of developing autoimmune type 1 diabetes (T1D) and should be appropriately screened.^1-6

The progression of autoimmune type 1 diabetes (T1D) is gradual, often detectable months or even years before symptoms arise.^1–3 Through proactive screening, we can identify the condition well in advance.³ Meet our ambassadors living with autoimmune T1D and discover the risk factors to look out for when considering who to screen.

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.^1-4 

The clinical benefits of early detection of T1D are being highlighted.^3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.^1,2

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.